TrialJournal for immunotherapy of cancer2022

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.

Lukas Rob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.